The Vision business at Johnson & Johnson MedTech has hit its latest milestone, earning a significant regulatory nod for its ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

Please provide your email address to receive an email when new articles are posted on . BARCELONA, Spain — In this Healio Video Perspective from the European Society of Cataract and Refractive ...

Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye surgeons a new lens option for use in ...

Please provide your email address to receive an email when new articles are posted on . Patients had good visual acuity at distance, intermediate and near. Most patients said they were satisfied with ...

FDA has approved Johnson & Johnson's Tecnis PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery. The new IOL will be available to U.S. patients ...

Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Johnson & Johnson (NYSE:JNJ) received FDA approval for its ...

Add Yahoo as a preferred source to see more of our stories on Google. The approval adds to J&J’s surgical vision portfolio Johnson & Johnson (J&J) has received approval from the US Food and Drug ...

JACKSONVILLE, Fla., March 12, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) ...